menu
    • menu
    [{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Interleukin-7","moa":"IL-7R","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"Toll-like receptor 3","graph1":"Oncology","graph2":"Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"Toll-like receptor 3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"Toll-like receptor 3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Progerinin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MT101-5","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"CytoDyn","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Oncology","graph2":"Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"CytoDyn","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"CytoDyn","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Sirnaomics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"STP705","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dry Powder","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Sirnaomics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"STP705","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Amytrx Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"AMTX-100","moa":"NFkB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Amytrx Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"AMTX-100","moa":"NFkB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Amytrx Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AMTX-100 CF","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Allarity Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"X-121","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"6","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"}]

    Find Clinical Drug Pipeline Developments & Deals by Amarex Clinical Research

    Menu

    Amarex Clinical Research

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Amarex Clinical Research

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Amarex Clinical Research

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rintatolimod

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Aim ImmunoTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-...

                            Details : Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity and evaluating Phase 2 Study for the Treatment of people with post-COVID conditions.

                            Product Name : Ampligen

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            October 07, 2023

                            Lead Product(s) : Rintatolimod

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Aim ImmunoTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Amarex Clinical Research

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Amarex Clinical Research

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMTX-100

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Recipient : Amytrx Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Amytrx Therapeutics Announces Open Enrollment for Phase 2b Clinical Trial of AMTX-100 CF3, a Promising Anti-In...

                            Details : AMTX-100 CF3, is a topical formulation anti-inflammatory peptide therapeutic designed to treat patients suffering from mild to moderate atopic dermatitis.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            June 28, 2023

                            Lead Product(s) : AMTX-100

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Amytrx Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Amarex Clinical Research

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Amarex Clinical Research

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MT101-5

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : Mthera Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 06, 2023

                            Lead Product(s) : MT101-5

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : Mthera Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Amarex Clinical Research

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Amarex Clinical Research

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Leronlimab

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Recipient : CytoDyn

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 16, 2023

                            Lead Product(s) : Leronlimab

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Recipient : CytoDyn

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Amarex Clinical Research

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Amarex Clinical Research

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rintatolimod

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Aim ImmunoTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            October 24, 2022

                            Lead Product(s) : Rintatolimod

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Aim ImmunoTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Amarex Clinical Research

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Amarex Clinical Research

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : X-121

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Allarity Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Co...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 07, 2022

                            Lead Product(s) : X-121

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Allarity Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Amarex Clinical Research

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Amarex Clinical Research

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMTX-100

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Recipient : Amytrx Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Amytrx Therapeutic's AMTX-100 CF3 Moves to Phase II Clinical Trial for Atopic Dermatitis

                            Details : AMTX-100 CF3, its leading drug candidate, is known for its ability to transport across membranes, address inflammation and modulate immune mediated diseases instead of simply inhibiting inflammation.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            September 06, 2022

                            Lead Product(s) : AMTX-100

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Amytrx Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Amarex Clinical Research

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Amarex Clinical Research

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rintatolimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Aim ImmunoTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            August 10, 2022

                            Lead Product(s) : Rintatolimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Aim ImmunoTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Amarex Clinical Research

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Amarex Clinical Research

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Leronlimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : CytoDyn

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            December 22, 2020

                            Lead Product(s) : Leronlimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : CytoDyn

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Amarex Clinical Research

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Amarex Clinical Research

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STP705

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Sirnaomics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carc...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            December 17, 2020

                            Lead Product(s) : STP705

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Sirnaomics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth